Роль половых гормонов в формировании и лечении артериальной гипертензии у женщин в перименопаузе и постменопаузе
Диссертация
Изучено влияние препаратов для заместительной гормональной терапии на сердечно-сосудистую и вегетативную нервную систему, предложен дифференцированный подход к назначению различных видов гормональной терапии у женщин в перименопаузе, в зависимости от состояния сердечнососудистой системы. Обоснованы принципы индивидуального подбора гормональной терапии у женщин групп риска по сердечно-сосудистым… Читать ещё >
Содержание
- ГЛАВА I. Обзор литературы
- 1. 1. ССЗ у женщин в постменопаузе
- 1. 2. Факторы риска развития ССЗ у женщин
- 1. 3. ЗГТ
Список литературы
- Андреева E.H. Эффективность и переносимость нового низкодозированного препарата для терапии климактерических расстройств «Анжелик» (эстрадиол+дроспиренон). Гинекология. 2005,7(2): 109−110.
- Глезер М.Г. Результаты Российского исследования эффективности и безопасности Диротона при артериальной гипертензии под контролем суточного мониторирования артериального давления DESIRE. Тендерные различия. Пробл. Женек. Здоровья. 2007−1:5−15.
- Доценко Ю.В., Лякишев A.A., Гончаренко Н. В., Старостина Т. А. Заместительная гормональная терапия у женщин с сердечно-сосудистой патологией. Лечащий врач, 2000.-N 7.-С.10−16.
- Зайдиева ЯЗ.// Заместительная гормонотерапия. Фармакология и клиническое применение. — Пособие для врачей. М. — 2001. — С. 6−8.
- Зызина Н.Е. Возможности оценки нейровегетативного и психоэмоционального статуса женщин пременопаузального периода в реализации и прогнозировании климактерического синдрома: Автореф. дис. канд. мед. наук. М., 2004.
- Караченцев А.Н., Кузнецова И. В. Терапия эстрогенами при артериальной гипертонии у женщин в климактерическом периоде // Проблемы эндокринологии, 2003, Т. 49, № 4. С. 51 — 54.
- Караченцев А.Н., Кузнецова И. В., Кобалава Ж. Д., Моисеев B.C. Заместительная гормональная и гипотензивная терапия в пери и постменопаузе у больных с артериальной гипертонией. Акушерство и гинекология, 2004, № 6:10−13.
- Кириченко A.A., Флегентова О. Н. Гипертензия и кардиалгии в климактерии. Лечащий врач, июль-август 2006- 6: 1−3
- Клинические рекомендации. Акушерство и гинекология. Выпуск 2/под редакцией В. И. Кулакова.- М.:ГЭОТАР-Медиа, 2008−560 с.
- Маслова Н.П., Баранова Е. И. Гипертоническая болезнь у женщин. СПб-2000
- Мартынов А.И., Майчук Е. Ю., Юренева C.B. и соавт. Артериальная гипертензия у женщин с хирургической менопаузой. В кн. «Медицина климактерия» под ред. В. П. Сметник, 2006. Изд-во. «Литера», 463−475.
- Подзолков В.Н., Брагина А. Е., Чурганова Л. Ю. Заместительная гормональная терапия новое направление в лечении и профилактике кардиоваскулярных нарушений в перименопаузе. Рос. Мед. журн. 1998−3: 2123.
- Руководство по климактерию/под ред. В. П. Сметник и В. И. Кулакова. М., 2001.
- Сметник В.П. От главного редактора. Климактерий, 2010−1:3−4.
- Сметник В.П., Ильина Л. М. Роль половых гормонов в развитии метаболических расстройств у женщин в пери- и ранней постменопаузе. Климактерий, 2009−1:8−13
- Сметник В.П. Медицина климактерия М.б 2008.
- Сметник В.П.// Consilium Medicum.-2001−3(11):546−558.
- Соболева Г. Н., Карпов Ю.А.// Рус. Мед. журнал.-2001 -9(9):383−386
- Ткачева О.Н., Майчук Е. Ю., Прохорович Е. А. Дислипидемия у женщин. Москва, Медицинская книга, 2007, 123 С.
- Шестакова И.Г. Заместительная гормонотерапия в климактерии: современные тенденции. Гинекология. 2009. 2(11): 19−23.
- Anderson GL, Limacher M, Assaf AR et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine in postmenopausal women withhysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004- 291−1701 12.
- Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vase Biol 2001−21:262−268.
- Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 2000−36:1786−1796.
- Archer D.F. Premature menopause increases cardiovascular risk. Climacteric 2009-(Suppl 1):26−31
- Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007- 10(Suppl 1):3—10.
- Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005−16(6):716−727.
- Archer DF. Lower doses of oral estrogen and progestogens as treatment for postmenopausal wonen. Semin Reprod Med 2005- 23: 188−95.
- Arnanz Velasco F, Andreu Sanchez JL. Controversies and facts about the hormonal replacement therapy for prevention of osteoporosis in postmenopausal women.// Rev Clin Esp. 2004 Feb-204 (2): 101−2.
- Atsma F., Bartelink MLEL., Grobbe DE et al/ Postmenopausal status and early menopause is independent risk factors for cardiovascular desease: a metaanalysis Menopause 2006- 13:265 -79.
- Bairey Merz CN, Johnson BD, Sharaf BL, et al, for the WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE Study. J Am Coll Cardiol 2003−41: 413−419.
- Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002−100:1209−1218.
- Basson R. Introduction to Special Issue on Women’s sexuality and outline of assessment of sexual problems. Menopause 2004- 11:709−13
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and the risk of cardiovascular disease and cancer in later life: a systematic review and metaanalysis. BMJ 2007−335:974−7
- Ben-Rafael Z. Polycystic ovarian syndrome (PCOS) in women in their forties. Meeting Abstracts of the 12-th World Congress on the Menopause. Climacteric 2008- 1 l (Suppl. 2), p.40
- Birkhauser MH, Panay N, Archer DF et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. 2008−11:108−123
- Boschitsch E., Mayerhofer S., Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010−13:307−313
- Bromberger JT, Meyer PM, Kravitz HM, Sommer B, Cordal A, Powell L, Ganz PA, Sutton-Tyrrell K. Psychologic distress and natural menopause: a multiethnic community study.// Am J Public Health. 2001 Sep-91 (9): 1435−42.
- Brzezinsky A. Does postmenopause actually begin before menopause Menopause 2008−15:1045−1047
- Burger H.G. Hormone therapy in the WHI era. J Obstet Gynaecol 2006- 46(2):84−91.
- Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004- 190 (4- suppl.): 15−22.
- Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review. Clin Interv Aging. 2009- 4: 59−62.
- Carranza-Lira S. Actualidades en terapia hormonal. Universum-Mexico.2008.
- Carranza-Lira S, Cortes-Fuentes E. Modifi cation of vasomotor symptoms after different treatment modalities in the postmenopause. Int J Gynaecol Obstet. 2001 -73 (2): 169−171.
- Cimoncini T., Fu X-D., Caruso A. et al. Human Reprod 2007- 22(8): 2325—2334
- Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002−23:665 -686.
- Chase NL, Sui X, Lee DC, Blair SN. The association of cardiorespiratory fitness and physical activity with incidence of hypertension in men. Am J Hypertens. 2009 Apr-22 (4):417−24.
- Cherry N, Gilmour K, Hannaford P, et al, for The ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002−360: 2001−2008.
- Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Climacteric. 2005 Oct- 8 Suppl 3:35−41.
- Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003−289:2560−72
- Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heartdisease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002−109:1056−1062.
- Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Eur Heart J 2007−28:2028−40
- Conroy RM, Pyorala K, Fitzgerald AP el. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003−24:987−1003
- Crook D. Postmenopausal hormone replacement therapy, lipoprotein metabolism, and coronary heart disease.// J. of Cardiovasc. Pharmacol.-1996, Vol.28, pp.40−45
- Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy.// Brit. J. Obstet. and GynecoL-1997, Vol. 104, pp.4−13
- Davis SR, Dinatale I, Rivera-Woll L, Davison S. Postmenopausal hormone therapy: from monkey glands to transdermal patches. J. Endocrinol 2005- 185:207 -22.
- Duda G, Wrobel J, Przyslawski J. Tobacco smoking and frequency of arterial hypertension in students of Poznan universities. Przegl Lek. 2008−65 (10):458−61.
- Dubey RK, Imthurn B, Barton M et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovascular Res 2005−66:295−306
- Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003−68:891 -905.
- European Expert Workshop: Practical Recommendations for HRT. Climacteric 2004- 7:210.
- Farquhar CM, Marjoribanks J, Lethaby A et al. Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2005-Vol. 20(3) :CD004143.
- Fenton A., Pana N. Management of polycystic ovary syndrome in postmenopausal women: a medical black hole. Climacteric 2008- 11:89—90
- Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy. Menopause. 2001 -8 (6):420−423.
- Foidart JM. Added benefits of drospirenone for compliance. Climacteric. 2005 Oct 8 Suppl 3:28−34.
- Gambacciani M, Ciaponi M, Cappagli В et al. Prospective evaluation of body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001: 39: 125 32.
- Gast GC et al. Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women. Maturitas 2010−66:285−290
- Genazzani A. Drospirenone: the only progestogen similar to natural progesterone. Климактерий, 2008−4:11−12.
- Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. IMS Statement following 6th IMS Workshop, Pisa, December 2006. Climacteric 2007−10:88−96
- Gerber LM et al. Hot flushes are associated with increased ambulatory systolic blood pressure. Menopause 2007−14:308−315
- Giretti M., Goglia L., Tosi V. The effects of drospirenone on the breast. Gynaecology Forum 2008−13:18−21
- Grady D, Herrington D, Bittner V et. al. Cardiovascular disease outcomes during 6,8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 2002 288:49−57
- Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in communitydwelling elderly women. Am J Med 2005−118:1232−1239.
- Grodstein F, Manson JE, Stampfer MJ et al. Postmenopausal hormone therapy and stroke: role of tome since menopause and age at initiation of hormone therapy. Ann Intern Med 2008- 168: 861−6.
- Grodstein F., Manson JE, Stampfer MJ. Hormone therapy and coronary beat deasease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larcbmt) 2006- 15:35−44
- Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003- 348:645−650.
- Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’Health Study: a prospective, observational study. Ann Intern Med 2001−135:1−8
- Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000
- Guthrie J.R., Dennerstein L., Taffe J.R., Lehert P., Burger H.G. The menopausal transition: a 9-year prospective populationbased study. The Melbourne Women’s Midlife Health Project. Climacteric 2004−7:375−89
- Halm J, Amoako E. Physical activity recommendation for hypertension management: does healthcare provider advice make a difference? Ethn Dis. 2008 Summer- 18 (3):278−82.
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988−2000. JAMA. 2003−290:199−206
- Harman SM. Estrogen replacement in menopausal women: Recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006−3 (4):254−269.
- Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005−8:3 -12.
- Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 2006−47:609 -613.
- Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med 2005−2:317−30
- Heckbert SR, Kaplan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001- 161:1709−1713.
- Hernandez S. I., Raij L. Am J Nephrol 2006−26:170−80-
- Hernandez Schulman I., Aranda P., Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006−47:1168 -74.
- Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al, for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on stroke in the Women’s Health Initiative: a randomized trial. Circulation 2006−113:2425−2434
- Hersh AL, Stefanick ML, Stafford RS. National use of postmeno-pausal hormone therapy: annual trends and responses to recent evidence. JAMA 2004−291:47−53.
- HerringtonDM, ReboussinDM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. NEngl JMed.2000−343:522 -529.
- Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
- Quality-of-life and depressive symptoms in post-menopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002−287:591−597
- Hsia J, Langer D, Manson JE, et al. Conjugated equine estrogens and the risk of coronary heart disease. Arch Intern Med. 2006−166: 357−365.
- HodisHN, MackWJ. Postmenopausalhormone therapy in clinical perspective. Menopause 2007- 14:1−14
- Huber JC. Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women. Womens Health (Lond Engl). 2007 Jul-3 (4):409−15.
- Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002- 137:273 -284.
- Jonsdottir LS., Sigfusson N, Gudnason V et al. Do lipids, blood pressure, diabetes and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002−39:125−32
- Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002−162:1737−45
- Karim R., et al. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008−93(l):131−8
- Khraibi AA. Renal interstitial hydrostatic pressure and sodium excretion in hypertension and pregnancy. J Hypertens Suppl 2002- 20:21 7.
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000−62:29 -38.
- Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Effi cacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007−57 (4):361−369.
- Leiblum SR, Koochaki PE, Rodenberg CA, et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS). Menopause 2006- 13:46 -56.
- Levine JP. Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis.// Curr Womens Health Rep. 2003 Jun-3 (3):181−6.
- Lin JW, Caffrey JL, Chang MH, Lin YS.J. Sex, menopause, metabolic syndrome, and all-cause and causespecific mortality—cohort analysis from the Third National Health and Nutrition Examination Survey Clin Endocrinol & Metab 2010−95(9):4258−4267
- Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climacteric 2007−10(Suppl 2): 1−4
- Lobo RA. Evaluation of cardiovascular event rates with bormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004- 164: 482 4.
- Lokkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006−53 :226−233.
- Mack WJ., Slater CC, Xiang M et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004- 82:391−7
- Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging. 2007−24 (6):453−466.
- Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart diseaseVwhy renew the focus on the early years of menopause? Am J Epidemiol 2007- 166: 511−517.
- Manson JE, Hsia J, Johnson KC, et al- Women’s Health Initiative Investigators. Estrogen plus progestin and risk of coronary heart disease. N Engl J Med.2003−349 :523−534.
- Margolis KL, Bonds DE, Rodabough RJ et al. Effects of estrogen plus progestin on the incidence of diabetes in postmenopausal women: the results from Women’s Health Initiative hormone trial. Diabetologia 2004−47 :1175—87.
- Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005−308:1583−7
- Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002- 90(1 A): 3 -6 °F.
- Meneton PG, Warnock D. Involvement of renal apical Na transport systems in the control of blood pressure. Am J Kidney Dis 2001- 37 (1 suppl 2): 39 47.
- Mercuro G, Zoncu S, Saiu F, et al. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 2004- 47:131 8.
- Meyer PM, Powell LH, Wilson RS, Everson-Rose SA, Kravitz HM, Luborsky JL, Madden T, Pandey D, Evans DA. A population-based longitudinal study of cognitive functioning in the menopausal transition.// Neurology. 2003 Sep 23−61 (6):801−6.
- Mosca L, Banka CL, Benjamin EJ, et al. Evidence based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007−115:1481
- Mueck A. O., Seeger H. Combination of hormone therapy with sartan: an option for hypertensive postmenopausal women? Menopause 2008- 15:159—11
- Naftolin F, Schneider HP, Sturdee DW, et al. Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004−7:333−7
- Nasr A., Breckwoldt M.// Estrogen replacement therapy and cardioprotection: lipid mechanisms are the tip of an iceberg.-Gynecol.Endocrinol.-1998, Vol.12, pp.43−59
- Nielsen TF, Ravn P, Pitkin J, Christiansen C. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 2006−53 :184−190.
- Norman R.J., Flight I.H., Rees M. CM Oestrogen and progestogen hormone replacement therapy for perimenopausal and postmenopausal women: weight and body fat distribution.-Cochrane database Syst.-2000, Vol.2, pp. 10 101 018
- Oelkers W. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005- 8 (Suppl 3): 19−27
- Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004- 217 (l-2):255−261.
- Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005- 294: 183−193.
- Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). J Epidemiol. 2010 May 5−20(3):185−91. Epub 2010 Apr 17.
- Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol. 2004- 286: R233-R249.
- Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006−47:1741−53.
- Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006 Nov 20−55 (4):297−307. Epub 2006 Sep 1.
- Pechere-Bertschi A., Burnier M. Am J Hypertens 2004−17:994−1001
- Perez JA, Garcia FC, Palacios S, Perez M. Epidemiology of risk factors and symptoms associated with menopause in Spanish women. Maturitas. 2009 Jan 20−62 (l):30−6. Epub 2008 Nov 17.
- Perchere-Betschi A, M. Bunier. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004- 17:994—1001
- Pines A, Sturdee DW, MacLennan AH et al. The heart of the study: time for hormone therapy policies to be revised. Climacteric 2007−10:267−269
- Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004- 7: 8−11.
- Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease. Am J Epidemiol. 2006−163:589−59
- Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/n-P-Estradiol in hypertensive postmenopausal women receiving Enalapril. American Journal of Hypertension 2005−18: 797—804.
- Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/17b-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J of Hypertens 2002- 15:816−22.
- Pyoralo K, Lehto S, De Bacquer D, et al.- EUROASPIRE I Group- EUROASPIRE II Group. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Finding from the EUROASPIRE I and II surveys. Diabetologia 2004- 47: 1257 65.
- Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother. 2007 May-8(7):989−99.
- Reckelhoff JF Basic research into the mechanisms responsible for postmenopausal hypertension. Int J Clin Pract 2004- 58 (Suppl 139) — 13−19
- Riibig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and anti-androgenic properties. Climacteric 2003−6 (Suppl 3):49−54.
- Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007−297- 1465−1477.
- Rossouw JE. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. Maturitas. 2005- 51:51−63.
- Rosano G., Vitale C., Fini M. Statins for prevention of cardiovascular disease in women: one size fit all? Climacteric 2008−11:347—350
- Rosano G. Menopause and cardiovascular disease the evidence. Abstract book. 12th International Congress on Gynecological Endocrinology- March 2−5, 2006, Florence, Italy, p. 12−13
- Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol. 2001- 280: H1699-H1705.
- Quyyumi AA. Women and ischemic heart study: pathophysiologic implications from the Women’s Ischemia Syndrome Evaluation (WISE) Study and future research steps. J Am Coll Cardiol 2006 47(3 Suppl): 66−71
- Sabia S, Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Risk factors for onset of menopausal symptoms: results from a large cohort study. Maturitas. 2008 Jun 20- 60(2): 108−21. Epub 2008 May 29.
- Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women: a metaanalysis. Gen Intern Med 2006−21:363−6
- Salpeter SR, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: ameta-analysis. J Gen Intern Med 2004−19:791−804
- Samsioe G. Hormone replacement therapy and cardiovascular disease.// J. Of cardiovascular Pharmacology.-1996, Vol. 28, pp. 51−57.
- Sampanis C, Zamboulis C. Arterial hypertension in diabetes mellitus: from theory to clinical practice. Hippokratia. 2008 Apr-12(2):74−80.
- Sare GM, Gray LJ, Bath PHW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008−29:2031−41
- Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and effi cacy of three dose regimens. Climacteric. 2004−7(2): 189−196.
- Seeger H.- Wallwiener D., Mueck A. O. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009−12:80−87
- Sevre K, Lefrandt JD, Nordby G, et al. Autonomic function in hypertensive and normotensive subjects: the importance of gender. Hypertension 2001- 37:1351−6.
- Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001- 103: 638−642.
- Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005- 8 Suppl 3:4−12.
- Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004- 47(4):277−283.
- Scmidt-Gollwitzer K. Estrogen/hormone replacement therapy present and past. Gynecol Endocrinol 2001- 15 (suppl. 4): 11−6.
- Shelley J.M., Green A., Smith A.M. et al. Relationships of endogenous sex hormones to lipids and blood pressure in midwaged women. Ann. Epidemiol. 1998- 8(l):39−45.
- Shulman LP. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am J Cardiol. 2002 Jun 20- 89(12A):47E-54E- discussion 54E-55E.
- Skurnick JH, Weiss G, Goldsmith LT et al. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms published online ahead of print May 20, 2008. Fertil Steril 2008
- Sowers M.F., Tisch J.// Insulin resistance, body weight, obesity, bodycomposition, and the menopausal transition.-in book: Menopause: Biology and Pathobiology. -Academic Press.-2000, pp.245−260
- Studd J. Variations on hormone replacement therapy: an answer to the 'one dose fits all’Women’s Health Initiative study. Gynecol Endocrinol 2007−23:665−71
- Taddei S. Blood pressure through aging and menopause. Climacteric 2009- 12 (Suppl l):36−40
- Tank LB, Bagger YZ, Oin G et al. Enlarged waist combined with elevated triglycerides is a strong predictor faccelerated atherogenesis and related cardiovascular mortality in postmenopausal women Circulation 2005−111:1883— 90.
- Tank LB, Christiansen C. Effects of 17 beta-oestradiol plus different dose of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J. Intern Med 2005 Dec- 258 (6):544−53
- Thurston RC et al. Hot flashes and subclinical cardiovascular disease: Findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008−118:1234−1240
- Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas. 1996 Mar-23(2):209−16.
- Tsuda K. A new hormone therapy with drospirenone and NO production in postmenopausal women. Hypertension. 2006 Nov-48(5):el06- author replyel07. Epub 2006 Sep 25.
- Tsuda K, Kinoshita Y, Nishio I. Synergistic role of progesterone and nitric oxide in the regulation of membrane fluidity of erythrocytes in humans: an electron paramagnetic resonance investigation. Am J Hypertens. 2002- 15: 702−708
- Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001- 345:1291−7
- Vitale C., Rosano G. Hypertension: the most relevant modifiable risk factor for cardiovascular disease during the menopause. Gynecol Forum 2007−2: 6—10.
- Vitale K., Rosano D. Hypertension: the most relevant modifiable risk factor for cardiovascular during the menopausedisease. Gynaecol Forum 2007- 12: 10— 14
- Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002−9: 402−410.
- Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001- 756(6): 1065−1079.
- Ylikorkala O. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.Climacteric. 2005−8 Suppl 3:1−3.
- Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone in a continuous combination with 17b-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004- 7: 103−11.
- Wassertheil-Smoller S, Hendrix SL, Limacher M et al. WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003- 289: 2673 84.
- Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertehtion and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension. 2000- 36:780−789.
- Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002−288: 24 322 440.
- Wildman R. P., Colvin A.B., Powell L.H. Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women’s Health Across the Nation (SWAN). Menopause 2008- 15:414—421.
- White W.B. Drospirenone in the postmenopausal women with hypertension. Abstract book. 12th International Congress on Gynecological Endocrinology- March 2−5, 2006, Florence, Italy, p. 14−15
- White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003- 41: 1021−1026
- White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003- 92: 382
- Whitehead M. Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data. J Br Menopause Soc 2006- 12 (Suppl l):4−7.
- Wolff EF, Narayan D, Taylor HS. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril 2005−84: 285−288.
- Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006 Jul-Aug- 13(4):643−50.